Learn more about Genomic Health's diagnostic tests for breast, colon and prostate cancer, which can help patients and their doctor make better, more informed treatment decisions.
Watershed TAILORx trial finds 99 percent of women with low Oncotype DX Recurrence Scores® are free of breast cancer recurrence after five years of hormone therapy alone. Learn more about this historic study published in the New England Journal of Medicine.
Lead TAILORx investigator Dr. Joseph Sparano discusses study results
For over a decade, Genomic Health has made genomics an indispensable part of cancer care. Now, we are using next generation technology to transform patient management throughout the cancer journey: from diagnosis to treatment, and monitoring for recurrence. Learn more about how we are making cancer treatment smarter today and tomorrow.
CMS Releases Final 2016 Clinical Lab Fee Schedule (CLFS) Including Gap-fill Pricing for Oncotype DX® Colon Canc...
Genomic Health Announces Presentation of Eight Oncotype DX® Studies at the 2015 CTRC-AACR San Antonio Breast Ca...
All press releases